



HIF-1α Pulmonary Phenotype Wide Association Study Unveils a Link to Inflammatory Airway Conditions

Jelte Kelchtermans^{1,2,*†}, Xiao Chang^{2†}, Michael E. March², Frank Mentch², Patrick M. A. Sleiman² and Hakon Hakonarson^{1,2}

¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States, ²The Center of Applied Genomics, The Children's Hospital of Philadelphia, Philadelphia, PA, United States

Despite experimental data linking HIF-1 α dysfunction to inflammatory airway conditions, the effect of single nucleotide polymorphisms within the *HIF1A* gene on these conditions remains poorly understood. In the current study, we complete a phenotype wide association study to assess the link between SNPs with known disease associations and respiratory phenotypes. We report two SNPs of the *HIF1A* gene, the intronic rs79865957 and the missense rs41508050. In these positions the A and the T allele are significantly associated with allergic rhinitis and acute bronchitis and bronchiolitis, respectively. These findings further support the role of HIF-1 α in inflammatory pulmonary conditions and may serve as a basis to refine our understanding of other HIF-1 α associated phenotypes.

OPEN ACCESS

Edited by:

Lei Wang, Changsha University, China

Reviewed by:

Yulin Dai, University of Texas Health Science Center at Houston, United States Yongzhang Zhu, Shanghai Jiao Tong University, China

*Correspondence:

Jelte Kelchtermans kelchtermj@chop.edu

[†]These authors have contributed equally to this work and share first authorship

Specialty section:

This article was submitted to Computational Genomics, a section of the journal Frontiers in Genetics

Received: 10 August 2021 Accepted: 08 September 2021 Published: 21 September 2021

Citation:

Kelchtermans J, Chang X, March ME, Mentch F, Sleiman PMA and Hakonarson H (2021) HIF-1α Pulmonary Phenotype Wide Association Study Unveils a Link to Inflammatory Airway Conditions. Front. Genet. 12:756645. doi: 10.3389/fgene.2021.756645 Keywords: phenotype, hypoxia inducible factor, inflammation, airway, HIF1A, rhinitis, bronchiolitis, SNP

INTRODUCTION

Hypoxia inducible factor (HIF) is central in the mammalian response to hypoxia. (Majmundar et al., 2010) HIF-1 is a nuclear factor that consists of a Hypoxia inducible factor 1α (HIF- 1α) and a Hypoxia inducible factor 1β (HIF-1β) subunit. (Wang and Semenza, 1993; Gladek et al., 2017) While HIF-1β is stable regardless of the oxygen concentration, HIF-1 α is rapidly degraded under normoxic conditions. (Yu et al., 1998; Gladek et al., 2017) Under hypoxic conditions however, HIF-1a is stabilized, leading to formation of HIF-1. (Ke and Costa, 2006; Slemc and Kunej, 2016) HIF-1 then in turn acts as a transcription factor, affecting over 98 target genes associated with up to 20 biological pathways. (Ke and Costa, 2006; Slemc and Kunej, 2016) Given this central role, it comes as no surprise that variations within the highly conserved HIF1A gene have been associated with a wide array of pathologic conditions. (Majmundar et al., 2010) Apart from playing an important role in normal lung development, HIFs have been shown to play a central role in the development of multiple pulmonary conditions, including pulmonary hypertension, Chronic obstructive pulmonary disease (COPD) and lung cancer angiogenesis. (Shimoda and Semenza, 2011) Despite this, within pulmonology, to date, variations within the HIF1A gene have only been associated with COPD and lung cancer. (Chan et al., 2017; Gladek et al., 2017; Paradowska-Gorycka et al., 2018; Wang et al., 2018; Hoang et al., 2019; Huang et al., 2020) Our current study sets out to examine the association between single nucleotide polymorphisms (SNPs) in the HIF1A gene and respiratory phenotypes. By starting with SNPs of interest, the Phenotype Wide Association Study (PheWAS) design flips the direction of inference commonly used in genome-wide association studies (GWAS). (Bush et al., 2016) To do so, it integrates data captured from patient's electronic health records (EHRs) with their genetic information. The major benefit of this approach is that it allows us to focus our efforts

1

TABLE 1 | Minor allele frequency for all SNPs included in the current study, unless otherwise indicated the data was pulled from the genome aggregation database (Karczewski et al., 2020).

SNP ID	Substitution	MAF
rs1957757	T>C	0.326-0.952
rs12434438	G>A	0.117-0.841 ^a
rs10873142	C>T	0.338-0.914
rs41508050	C>T	0.000292-0.0189
rs2301113	C>A	0.188-0.881
rs11549465	C>T	0.0366-0.155
rs11549467	G>A	0.000574-0.0431
rs199775054	G>C	0.000-0.001 ^b
rs113182457rs60361955	insGT	Unavailable
rs2057482	T>C	0.658-0.939
rs2783778	C>T	0.184–0.870
rs7148720	T>C	0.00575-0.151
rs1535679	A>C	0.185-0.872
rs28708675	A>T	0.000218-0.370
rs1319462	G>A	0.682-0.944
rs1957755	G>A	0.000-0.075
rs41362550	T>C	0.0283-0.0755
rs7143164	G>C	0.0485-0.523
rs1951795	A>C	0.227-0.913
rs12435848	A>G	0.249-0.912
rs2301104	G>C	0.000344-0.0147
rs10129270	G>A	0.0311-0.373
rs8005745	T>A	0.369-0.952
rs779897997	C>A	Unavailable
rs4899056	T>C	0.262-0.948
rs11158358	G>C	0.655-0.928
rs2301111	G>C	0.222-0.902
rs966824	T>C	0.717-0.977
rs41492849	C>T	0.0000648-0.0020
rs34005929	G>A	0.000459-0.00943
rs61755645	A>T	0.00161-0.0150
rs4902080	T>C	0.654-0.977
rs4902082	C>T	0.226-0.862
rs17099207	G>A	0.237-0.399
rs142179458	G>A	0.000574-0.0282
rs12434439	G>C	0.110-0.506
rs76308410	C>T	0.0621-0.149
rs74481028	A>G	0.0759-0.226
rs7161527	T>C	0.686-0.939
rs10147275	T>G	0.680-0.939
rs2301108	A>G	0.379-0.952
rs79865957	G>A	0.000230-0.00210

^aData from the Allele Frequency Aggregator (Phan Yj et al., 2020). ^bData from the 1000 Genomes Project (Auton et al., 2015).

specifically on SNPs with known disease associations within this master regulator gene, improving the likelihood that found associations are based on molecular mechanisms that are relevant to the disease phenotypes uncovered.

METHODS

Single Nucleotide Polymorphisms Selection

SNPs were selected from enriched literature review, including recently completed review by Gladek et al. (Gladek et al., 2017) All studies identified with keywords "HIF1a" and "variant" published after their literature review was completed, were reviewed. SNPs significantly associated with human disease were included in the current study (Table 1).

Population

Subjects were drawn from The Children's Hospital of Philadelphia (CHOP) biorepository at the Center for Applied Genomics (CAG). The pediatric samples included in this biorepository are linked to subjects' EMRs. All subjects have consented to both genomic analysis and EMR mining (Gottesman et al., 2013).

Genotype Imputation

Genotype data were generated by the Center for Applied Genomics on patients recruited from CHOP and were acquired four maior genotyping on arravs (HumanHapMap550, 610Q, OMNI2.5M and the GSA array). Where possible, data from similar arrays were merged. Data were filtered for genotype missingness (geno 0.1), individual missingness (0.02), and minor allele frequency (MAF) (0.01) using PLINK v1.9. (Chang et al., 2015) Data were imputed using the TOPMed v2 reference panel on the TOPMed Imputation Server. (Fuchsberger et al., 2015; Das et al., 2016; Taliun et al., 2021) Imputed genotypes were filtered on combinations of Rsq (imputation quality metric) and MAF [(MAF \geq 0.05 and Rsq > 0.3) OR (MAF < 0.05 and Rsq > 0.5)] using BCFTools v1.10.2, and only SNPs that remained in 85% of samples were retained for use in PheWAS analysis (Danecek et al., 2021).

Ancestry Identification

Subjects in the PheWAS cohort were separated by ancestry based on the results of principal component analysis (PCA). PCA was performed using flashpca on approximately 2.4 million imputed SNPs with MAF >0.01 that had been pruned for linkage disequilibrium using PLINK v1.9 (Abraham and Inouye, 2014; Chang et al., 2015) The first three principle components were plotted, and ancestry designation was performed by comparison to the reference genotypes from the HapMap consortium. (Altshuler et al., 2010) The complete dataset contained 71,600 individuals: 34,410 Caucasians, 31,507 African Americans, 2644 Hispanics, and 3039 East Asians.

PheWAS

A PheWAS was conducting using the published PheWAS R package from Carroll et al. (v0.99.5-5). (Carroll et al., 2014) International Classification of Diseases 9 (ICD-9) codes were obtained from an anonymized extraction of the Children's Hospital of Philadelphia diagnosis database that contained subjects that had been recruited into the patient collection of the Center for Applied Genomics. Counts of the occurrence of each ICD-9 code for each subject were generated, and the resulting table was converted into the PheWAS phenotype table by a function in the R package. Subjects were included in the case group for each PheWAS phenotype if they possessed two or more occurrences of any of the ICD-9 codes that composed the phenotype in question. Subjects were listed as controls for the PheWAS phenotype if they lacked the case-

European 573.3 Hepatomegaly r61755645 1.72803376 0.409801308 5.829574578 2.48E-05 107 30.894 TRUE 251.1 Hypoglycemia r61755645 1.33952494 0.337660972 3317229665 727E-05 264 28,003 FALSE 151.1 Magrent menohasm of liver, primary r61755645 1.11814428 0.2377680322 3177229665 7436 718794 FALSE 151.1 Poisonny/allegry of sulforantices r111811428 0.2375163224 0.339660017 666-05 243 181794 FALSE 696 Psorinsis and related disorders r124719458 7.1431736 0.44565292 0.7502124 118794 FALSE 678.3 Peptic uber (seci. esophagea) r1247179458 3.44013739 7.562-05 220 29124 FALSE 678.3 Peptic uber (seci. esophagea) r1427179458 3.44013736 1.4457316 3.345127319 7.567-05 291 7.24345 636 Fause r142779458 3.4401347387 1.14577024 3.456	Population	phecode	Description	dus	beta	Ю	SE	٩	n_cases	n_controls	bonferroni	fdr
Z51.1 Hypoglycemia rs81755645 1.33852444 0.337650972 3.317229653 7.27F-05 264 28,603 155.1 Malgner minits rs79865957 1.111814428 0.2377530388 3.03869017 6.66E-05 24348 18,794 155.1 Malgner minits rs74179458 7.05389598 1.24719458 2.05389599 3.03869017 6.66E-05 244 28,603 961.1 Psoring/allergy of sultomanides rs142179458 2.05386996 1.24637325 1.46E-62 1.18 28,003 696 Psoriasis and related disorders rs142179458 3.491251843 0.848041087 3.282701528 3.44E-05 7.2 28,655 558 Other descrices of intestine rs142179458 3.491251943 0.34011087 3.282701528 3.44E-05 7.2 28,655 578.9 Homorrhage of gastrointestinal tract rs142179458 3.491251843 0.848041087 3.56E-05 27 28,6415 578.9 Homorrhage of gastrointestinal tract rs142179458 3.4912517819 2.50E-05 21	European	573.3	Hepatomegaly	rs61755645	1.728033876	0.409801308	5.629574578	2.48E-05	107	30,884	TRUE	TRUE
476 Allergic rhinitis rs		251.1	Hypoglycemia	rs61755645	1.33952494	0.337650972	3.817229663	7.27E-05	264	28,603	FALSE	TRUE
155.1 Malgnant neoplasm of liver, primary 151/2458 2.97285E+15 B6170822.24 Inf 0 20 32.275 961.1 Poisoning/allegy of sulfonamides 151.4313765 1.46E+32 1.76E-05 118 28.063 961.1 Poisoning/allegy of sulfonamides 151.2413765 0.34011245 3.845127319 7.16E-05 118 28.063 963 Psprotisciess of netated disorders 151.274548 3.491251845 0.34011245 3.845127319 7.16E-05 118 28.063 569 Other disorders 151.2779458 3.491251845 0.34011245 3.845-05 72 28.568 578.9 Hemorrhage of gastrointestinal tract 151.2779458 4.169090079 1.137501266 64.56659292 0.00012732 20 29,609 578.9 Hemorrhage of gastrointestinal tract 151.42179458 4.169090079 1.137501266 64.56659292 0.00012732 20 29,609 300.9 Posttraumatic stress disorder 151.42179458 4.169090079 1.137501266 64.56659292 0.00012732 20<		476	Allergic rhinitis	rs79865957	1.111814428	0.278793888	3.039869017	6.66E-05	4348	18,794	FALSE	TRUE
961.1 Poisoning/allegy of sulfonamides rs142179458 74.05386998 17.24313765 1.45E+32 1.75E-05 118 28,063 0596 Psoriasis and related disorders rs28703675 1.346806715 0.340112245 3.845127319 7.50E-05 220 29,124 0506 Psoriasis and related disorders rs142179458 3.491251843 0.848041087 3.282701628 384E-05 72 28,568 550 Other disorders of intestine rs142179458 3.491251968 2.7.09844186 3.96E-05 97 28,861 5731 Peptic uber (excl. esophageal) rs142179458 3.491251968 5.4.6505026 0.00012732 20 29,663 5733 Hemorrage of excl. esophageal) rs142179458 3.4913073 0.100247213 31 27,843 5734 427,11 Parovarial supraventricular tachycardia rs142179458 3.4913073 0.000247213 31 27,643 300.9 Posttraumatic stress disorder rs142179458 3.44163397 1.1062919352 1.967110245 37,6E-05 21 23,		155.1	Malignant neoplasm of liver, primary	rs142179458	2.97285E+15	86170822.24	Inf	0	20	32,275	TRUE	TRUE
056 Psoriasis and related disorders rs28708675 1.346806715 0.340112245 3.45127319 7.50E-05 220 29,124 7 242 Thyrotoxicosis with or without gotter rs142179458 3.491251843 0.843041087 3.282701628 3.45E-05 72 28,558 569 Other disorders of intestine rs142179458 3.491251843 0.843041087 3.282701628 3.48E-05 72 28,656 573.1 Peptic ulcer (excl. esothageal) rs142179458 3.49125186 64.66565922 0.00012732 20 29,609 573.3 Hemorthage of gastrointestinal tract rs142179458 3.4913837 1.105701266 64.665659292 0.00012732 20 29,609 573.4 Paoxystal supersorticular tachycardia rs142179458 3.4013877 1.105701266 64.665659292 0.00012732 20 29,609 573.5 Jaunolice (not of reworm) rs142179458 3.4018387 1.1052919352 1.95710246 31 27,624 300.9 Posttraumatic stress disorder rs1451795 0.671463117		961.1	Poisoning/allergy of sulfonamides	rs142179458	74.05386998	17.24313765	1.45E+32	1.75E-05	118	28,063	TRUE	TRUE
n 242 Thyrotoxicosis with or without gotter rs142179458 3.491251843 0.848041087 32.82701628 3.84E-05 72 28,558 569 Other disorders of intestine rs142179458 3.29947623 0.80271968 27.09844186 3.95E-05 97 28,661 531 Peptic ulcer (excl. esophageal) rs142179458 4.401347385 1.148701204 81.56068832 0.00012732 20 29,609 578.9 Hemorrhage of gastrointestinal tract rs142179458 4.401347385 1.148701204 81.56068832 0.00012732 20 29,609 578.9 Hemorrhage of gastrointestinal tract rs142179458 3.94818387 1.106947085 51.44113103 0.000247213 31 27,843 300.9 Posttraumatic stress disorder rs142179458 3.94818387 1.106947085 51.44113103 0.000247213 31 23,629 300.9 Posttraumatic stress disorder rs142179458 0.67427052 0.162403177 2.05656818 2.176E-05 91 23,629 300.9 Posttraumatic stress disorder rs2301191 0.7205605023 0.162403177 2.056556818 2.07		696	Psoriasis and related disorders	rs28708675	1.346806715	0.340112245	3.845127319	7.50E-05	220	29,124	FALSE	TRUE
569 Other disorders of intestine rs142179458 3.29947623 0.80271968 27.09844186 3.96E-05 97 28,861 531 Peptic ulcer (excl. esophageal) rs142179458 4.401347385 1.148701204 81.56068832 0.00012732 20 29,609 578.9 Hemorrhage of gastrointestinal tract rs142179458 4.401347385 1.148701204 81.56068832 0.00012732 20 29,609 578.9 Hemorrhage of gastrointestinal tract rs142179458 3.94818387 1.106947085 51.84113103 0.000247213 31 27,843 427.11 Paroxysmal supraventricular tachycardia rs142179458 3.94818387 1.106947085 51.84113103 0.000247213 31 27,843 300.9 Posttraumatic stress disorder rs1451795 0.671467911 0.162403177 2.055471038 2.1466 21,656730 20.6416 23,629 300.9 Posttraumatic stress disorder rs2301111 0.7205605023 0.162403177 2.055568187 2.0415 26,415 373.5 Jaundice (not of newborn) <td< td=""><td>African</td><td>242</td><td>Thyrotoxicosis with or without goiter</td><td>rs142179458</td><td>3.491251843</td><td>0.848041087</td><td>32.82701628</td><td>3.84E-05</td><td>72</td><td>28,558</td><td>TRUE</td><td>TRUE</td></td<>	African	242	Thyrotoxicosis with or without goiter	rs142179458	3.491251843	0.848041087	32.82701628	3.84E-05	72	28,558	TRUE	TRUE
531 Peptic ulcer (excl. esophageal) rs142179458 4.401347385 1.148701204 81.56068832 0.00012732 20 29,609 578.9 Hemorrhage of gastrointestinal tract rs142179458 4.401347385 1.137501266 64.656539292 0.00012732 20 29,609 578.9 Hemorrhage of gastrointestinal tract rs142179458 3.94818387 1.106947085 51.84113103 0.000247213 31 27,843 427.11 Paroxysmal supraventricular tachycardia rs142179458 3.94818387 1.106947085 51.84113103 0.000247213 31 27,843 300.9 Posttraumatic stress disorder rs1951795 0.671463911 0.162403177 2.055471008 91 23,629 300.9 Posttraumatic stress disorder rs2301111 0.7205605023 0.162403177 2.055471008 914E-06 91 23,629 379.2 Jaundice (not of newborn) rs34005929 5.02427052 1.198711093 1.20568187 0.00013874 2.33<61		569	Other disorders of intestine	rs142179458	3.29947623	0.80271968	27.09844186	3.95E-05	97	28,861	TRUE	TRUE
578.9 Hemorrhage of gastrointestinal tract rs142179458 4.168090079 1.137501266 64.65659292 0.000247213 31 27,843 427.11 Paroxysmal supraventricular tachycardia rs142179458 3.94818387 1.106947085 51.84113103 0.000247213 31 27,843 427.11 Paroxysmal supraventricular tachycardia rs142179458 3.94818387 1.106947085 51.84113103 0.000247213 31 27,843 300.9 Posttraumatic stress disorder rs1951795 0.671463911 0.1624903177 2.055471008 91 23,629 300.9 Posttraumatic stress disorder rs23001111 0.7205050233 0.162403177 2.055471008 914E-06 91 23,629 379.2 Jaundice (not of newborn) rs34005929 5.024227052 1.198711093 152.06268187 4.7591805 21.1484244 0.7142782183 20.64180095 4.56F-05 21 25,418 377.5 Jaundice (not of newborn) rs34005929 5.024227052 1.198711093 152.06268817 0.000138874 2234 21,468 377.7 Stepte feated movement disorders rs340055957 4.79138		531	Peptic ulcer (excl. esophageal)	rs142179458	4.401347385	1.148701204	81.56068832	0.00012732	20	29,609	FALSE	TRUE
427.11 Paroxysmal supraventricular tachycardia rs142179458 3.94818387 1.106947085 51.84113103 0.00036146 38 26,415 300.9 Posttraumatic stress disorder rs1951795 0.671463911 0.162919352 1.957100245 3.76E-05 91 23,629 300.9 Posttraumatic stress disorder rs2301111 0.720565023 0.162403177 2.055471008 9.14E-06 91 23,629 379.2 Disorders of vitreous body rs34005929 5.024227052 1.198711093 152.0554818 2.77E-05 21 23,629 379.2 Disorders of vitreous body rs34005929 5.024227052 1.198711093 152.055818 2.77E-05 21 23,629 379.2 Jaundice (not of newborn) rs34005929 5.02413192 0.742782183 20.64180095 4.59E-05 23 23,418 483 Acute bronchilitis and bronchilitis rs415080501 1.211842424 0.317605334 3.359668887 0.000135874 23 23,407 483 Acute bronchilitis and bronchilitis rs715080557 4.791384583 1.207332763 120.4680513 7.29E-05 25		578.9	Hemorrhage of gastrointestinal tract	rs142179458	4.169090079	1.137501266	64.65659292	0.000247213	31	27,843	FALSE	TRUE
300.9 Posttraumatic stress disorder rs1951795 0.671463911 0.162919352 1.957100245 3.76E-05 91 23,629 300.9 Posttraumatic stress disorder rs2301111 0.720565023 0.162403177 2.055471008 9.14E-06 91 23,629 379.2 Disorders of vitreous body rs34005929 5.024227052 1.198711093 152.0556818 2.77E-05 21 25,418 573.5 Jaundice (not of newborn) rs34005929 5.024227052 1.198711093 152.0556818 2.77E-05 21 25,418 573.5 Jaundice (not of newborn) rs34005929 5.02413182 0.742782183 20.64180095 4.59E-05 23 28,047 483 Acute bronchilitis and bronchilitis rs415080501 1.211842424 0.317605334 3.359668887 0.000135874 223 21,463 195 Cancer, suspected or other rs2301104 1.929317425 0.492152257 6.884809237 3.5616-05 35 2616 348 Other conditions of brain rs2301104 1.929317425 0.492152257 6.884809237 8.86E-05 25 2616 <tr< td=""><td></td><td>427.11</td><td>Paroxysmal supraventricular tachycardia</td><td>rs142179458</td><td>3.94818387</td><td>1.106947085</td><td>51.84113103</td><td>0.00036146</td><td>38</td><td>26,415</td><td>FALSE</td><td>TRUE</td></tr<>		427.11	Paroxysmal supraventricular tachycardia	rs142179458	3.94818387	1.106947085	51.84113103	0.00036146	38	26,415	FALSE	TRUE
300.9 Posttraumatic stress disorder rs2301111 0.720505023 0.162403177 2.055471008 9.14E-06 91 23,629 379.2 Disorders of vitreous body rs34005929 5.024227052 1.198711093 152.0556818 2.77E-05 21 25,418 573.5 Jaundice (not of newborn) rs34005929 5.024227052 1.198711093 152.056818 2.77E-05 21 25,418 483 Acute bronchitis and bronchiolitis rs34005929 3.027318192 0.742782183 20.64180095 4.59E-05 235 28,047 483 Acute bronchitis and bronchiolitis rs41508050 1.211842424 0.317605334 3.359668887 0.000135874 2234 21,463 327.7 Sleep related movement disorders rs739865957 4.791384583 1.207932763 120.4680513 7.29E-05 35 23,361 195 Cancer, suspected or other rs2301104 1.929317425 0.49215257 6.884809237 8.86E-05 25 2616 348 Other conditions of brain rs2301104 1.929317425 0.492152257 6.884809237 8.86E-05 51 2399 <td></td> <td>300.9</td> <td>Posttraumatic stress disorder</td> <td>rs1951795</td> <td>0.671463911</td> <td>0.162919352</td> <td>1.957100245</td> <td>3.76E-05</td> <td>91</td> <td>23,629</td> <td>TRUE</td> <td>TRUE</td>		300.9	Posttraumatic stress disorder	rs1951795	0.671463911	0.162919352	1.957100245	3.76E-05	91	23,629	TRUE	TRUE
379.2 Disorders of vitreous body rs34005929 5.024227052 1.198711033 152.0526818 2.77E–05 21 25,418 573.5 Jaundice (not of newborn) rs34005929 3.027318192 0.742782183 20.64180095 4.59E–05 235 28,047 483 Acute bronchitis and bronchiolitis rs41508050 1.211842424 0.317605334 3.359668887 0.000135874 2234 21,463 327.7 Sleep related movement disorders rs79865957 4.791384583 1.207932763 12.04680513 7.29E–05 35 23,361 195 Cancer, suspected or other rs2301104 1.923317425 0.492152257 6.884809237 8.86E–05 51 2399 348 Other conditions of brain rs739665957 -3.25556E+14 52249787.97 0 0 20 20 2474 801.1 Fracture of foot rs79865957 -3.25555E+14 52249787.97 0 0 20 20 2474		300.9	Posttraumatic stress disorder	rs2301111	0.720505023	0.162403177	2.055471008	9.14E-06	91	23,629	TRUE	TRUE
573.5 Jaundice (not of newborn) rs34005929 3.027318192 0.742782183 20.64180095 4.59E-05 235 28,047 483 Acute bronchilits and bronchiolitis rs41508050 1.211842424 0.317605334 3.359668887 0.000135874 2234 21,463 327.7 Sleep related movement disorders rs79865957 4.791384583 1.207932763 12.0.4680513 7.29E-05 35 23,361 195 Cancer, suspected or other rs2301104 1.929317425 0.492152257 6.884809237 8.86E-05 51 2399 801.1 Fracture of foot rs79865957 -3.25556E+14 52249787.97 0 0 20 20 2474		379.2	Disorders of vitreous body	rs34005929	5.024227052	1.198711093	152.0526818	2.77E-05	21	25,418	TRUE	TRUE
483 Acute bronchilitis and bronchiolitis rs41508050 1.211842424 0.317605334 3.359668887 0.000135874 2234 21,463 327.7 Sleep related movement disorders rs79865957 4.791384583 1.207932763 12.0.4680513 7.29E-05 35 23,361 195 Cancer, suspected or other rs2301104 2.851754693 0.671497479 17.31814322 2.17E-05 25 2616 348 Other conditions of brain rs2301104 1.929317425 0.492152257 6.884809237 8.86E-05 51 2399 801.1 Fracture of foot rs79865957 -3.25556E+14 52249787.97 0 0 20 20 2474		573.5	Jaundice (not of newborn)	rs34005929	3.027318192	0.742782183	20.64180095	4.59E-05	235	28,047	FALSE	TRUE
327.7 Sleep related movement disorders rs79865957 4.791384583 1.207932763 120.4680513 7.29E-05 35 23,361 195 Cancer, suspected or other rs2301104 2.851754693 0.671497479 17.31814322 2.17E-05 25 2616 348 Other conditions of brain rs2301104 1.929317425 0.492152257 6.884809237 8.86E-05 51 2399 801.1 Fracture of foot rs79865957 -3.25556E+14 52249787.97 0 0 20 2474		483	Acute bronchitis and bronchiolitis	rs41508050	1.211842424	0.317605334	3.359668887	0.000135874	2234	21,463	FALSE	TRUE
195 Cancer, suspected or other rs2301104 2.851754693 0.671497479 17.31814322 2.17E-05 25 2616 348 Other conditions of brain rs2301104 1.929317425 0.492152257 6.884809237 8.85E-05 51 2399 801.1 Fracture of foot rs79865957 -3.2555E+14 52249787.97 0 0 20 2474		327.7	Sleep related movement disorders	rs79865957	4.791384583	1.207932763	120.4680513	7.29E-05	35	23,361	FALSE	TRUE
Other conditions of brain rs2301104 1.929317425 0.49215257 6.884809237 8.85E-05 51 2399 Fracture of foot rs79865957 -3.2555E+14 52249787.97 0 0 20 2474	Asian	195	Cancer, suspected or other	rs2301104	2.851754693	0.671497479	17.31814322	2.17E-05	25	2616	TRUE	TRUE
Fracture of foot rs79865957 -3.2555E+14 52249787.97 0 0 20 2474		348	Other conditions of brain	rs2301104	1.929317425	0.492152257	6.884809237	8.85E-05	51	2399	TRUE	TRUE
		801.1	Fracture of foot	rs79865957	-3.2555E+14	52249787.97	0	0	20	2474	TRUE	TRUE

defining ICD-9 codes, as well as ICD-9 codes corresponding to closely related phenotypes. Conversion from ICD-9 codes to PheWAS phenotypes was performed using the default translation table included in the R package. Phenotypes were analyzed in the PheWAS if they were represented by 20 or more cases in the cohort. The subject's sex and age were included as covariates in the analysis, as were the 10 flashpca generated principle components and a variable representing the group in which genotyping array had been imputed. Genotypes were extracted from the imputed data as allele dose information to preserve some information regarding genotype probability, and the allele doses were used as the genotype inputs to the PheWAS. The PheWAS analysis was performed individually on each PCAdefined ancestry, and then a meta-analysis was performed combining all four ancestries using the PheWAS-meta function provided in the PheWAS R package. For the association test, a logistic regression model, adjusted for age and sex was used. For defining significance in this study, we set a FDR threshold of 0.05. As a total of 2146 traits were analyzed, the over-conservative significance threshold based on Bonferroni correction was $p = 2.3 \times 10^{-5}$.

In Silico Validation

SNP's significantly associated with respiratory disease were validated in an independent cohort by querying the publicly available Open Target Genetics database. (Ghoussaini et al., 2021) The Ensembl VEP was then used to assess the likely effect of these variants. (McLaren et al., 2016) To assess chromatin state and regulatory potential associated with the locations of the SNPs, other publicly available databases including Haploreg and Encode were queried.

RESULTS

We found 42 SNPs that have been previously associated with different medical conditions, including various cancers, cardiovascular diseases, metabolic disorders and (auto) immune diseases. This includes the 34 SNPs identified by Gladek et al. (Gladek et al., 2017) In addition, eight more SNPs were identified in studies published after their literature review was completed (Chan et al., 2017; Paradowska-Gorycka et al., 2018; Wang et al., 2018; Hoang et al., 2019; Huang et al., 2020).

Of the 42 SNPs included in our PheWAS, nine were significantly associated with at least one disorder. **Table 2** summarizes the data for all the SNP-phenotype associations passing False Discovery Rate (FDR) or Bonferroni test. Most of the detected associations were from cohorts with less than 500 cases. However, the A allele of SNP rs79865957 was found to be significantly associated with allergic rhinitis (**Figure 1**) in a European cohort of 4,348 cases and 18,794 controls with an allele frequency of 0.08%. The OR was 2.86, Beta 1.05, SE 0.25 and *p*-value 3.48E–05. The second, rs41508050, the T allele was significantly associated with acute bronchitis and bronchiolitis (**Figure 2**) in an African American cohort of 2,234 cases and 21,463 controls with an

TABLE 2 | SNP-phenotype associations passing False Discovery Rate (FDR) or Bonferroni test





allele frequency of 0.18%. The OR was 0.32, Beta 1.21, SE 3.36 and *p*-value 0.0001.

Using the Open Target Genetics database rs79865957, the A allele was found to have been previously positively associated with

both chronic airway obstruction (OR 1.94, *p*-value 0.0019, Beta 0.663) and asthma (OR 1.34, *p*-value 0.033, Beta 0.292). It has also been negatively associated with paternal chronic bronchitis/ emphysema (OR 0.75, *p*-value 0.0069, Beta -0.293). Using

Location	rs79865957	rs41508050
Reference allele	G	С
Varriant allele	А	Т
Regulatory region?	Yes	Yes
Constrained sequence?	No	Yes
DNAse hypersensitivity site?	In fetal fibroblast line	In lung carcinoma cell line
Associated Histone markers	H3K4me1_Enh and H3K27ac	H3K27ac_Enh
Encode	No proteins bound	RFX5 bound

Ensemble Variable Effect Predictor (VEP), it was found to be a likely intron variant for *HIF1A*. For rs41508050, the T allele was previously negatively correlated with "Bring up phlegm/sputum/ mucus on most days" (OR 0.72, *p*-value 0.0026, Beta –0.328) and is a missense variant for *HIF1A*.

The publicly available HaploReg tool was queried for both SNPs. SNP rs79865957 has four SNPs in linkage disequilibrium ($r2 \ge 0.8$), two of which (rs76269977 and rs142660658) are intronic in the *HIF1A* gene. It is located in a regulatory region but not in a constrained sequence. It has histone H3K4me1_Enh enhancer marks in a lung carcinoma line and both H3K4me1_Enh and H3K27ac in a fetal lung fibroblast line. It is also a DNAse hypersensitivity site in a fetal lung fibroblast line. SNP rs41508050 has no other SNPs in linkage disequilibrium, is in a regulatory region and in a constrained sequence both by Genomic Evolutionary Rate Profiling and SiPhycons. It has histone H3K27ac_Enh marks in both lung fibroblast and lung carcinoma lines and is a DNase hypersensitivity site in a lung carcinoma cell line. Looking at Encode it had RFX5 bound in the GM12878 lymphoblastoid cell line. (**Table 3**)

DISCUSSION

We present the results of a HIF-1a PheWAS analysis focused on association with respiratory phenotypes. We identified two SNPs that are significantly associated with respiratory disease. Given the allele rarity in our patient population, the Open Target Genetics database was queried in further support. This resource integrates knowledge derived from the UK Biobank with published data from other sources and provides an independent cohort to validate our findings. (Baumann and Cabassa, 2020) The prior associations with allergic airway disease in the form of asthma for rs79865957 and association with bringing up phlegm/sputum/mucus for rs41508050 are consistent with the respective associations with allergic rhinitis and acute bronchitis and bronchiolitis in our cohort, suggesting the association may be driven by the underlying biological "inflammation" process which is the central driver across all these phenotypes involving different organs. To address the likely impact of these variants we used the Ensembl VEP and the publicly available HaploReg tool (Ward and Kellis, 2012; McLaren et al., 2016), both of which underscore the possible significance of both variants. Adding to the evidence supporting a functional impact are the previously published associations between rs79865957 and diabetic kidney disease and between rs41508050 and angina versus myocardial infarction as initial presentation of coronary disease (Hlatky et al., 2007; Huang et al., 2020).

Previously, variations within the HIF1A gene have been associated with COPD, lung cancer and a host of nonpulmonary conditions. (Gladek et al., 2017) Both the SNPs reported here had prior significant disease associations. First, rs79865957 was previously associated with diabetic kidney disease in a Han Chinese population. (Nava-Salazar et al., 2011) While to our knowledge the functional consequences of this SNP have not been eluded, the authors hypothesized that in a high glucose environment HIF1A transcription may be stimulated. Additionally, rs41508050 has a known association with the development of stable angina as opposed to myocardial infarction as initial presentation of coronary artery disease. (Hlatky et al., 2007) In vitro studies have previously linked this variant with a higher transcriptional activity. (Nava-Salazar et al., 2011) However, to our knowledge, the current study is the first to report on the association between SNPs of the HIF1A gene and allergic rhinitis, acute bronchitis and bronchiolitis. The reported association with allergic rhinitis is consistent with previously published experimental data highlighting the role of HIF-1a in allergic airway pathology. In an allergic airway disease model, HIF-1a inhibition decreased Th2 inflammation as measured by reduced IL-4, IL-5 and IL-13. (Kim et al., 2010) Beyond this, in a mouse model downregulation of HIF-1 or blockade of HIF-1a reduced cellular infiltrate in peribronchial lung tissues, thickness of smooth muscle and eosinophil infiltration. (Huerta-Yepez et al., 2008) Likewise, the role of HIF-1a in bronchiolitis is supported by experimental data on the consequences of HIF-1a stabilization by the Respiratory Syncytium Virus. (Kilani et al., 2004)

Traditionally, GWAS identify SNPs significantly associated with human disease. These findings are then used to guide animal studies aiming to prove a causal link between the SNP and the disease. As briefly discussed above, the PheWAS design flips this process. It allowed us to look specifically at a highly conserved gene known to play a central role in the diseases of interest. In doing so, we were able to narrow down the list of SNPs within the *HIF1A* gene that play a potential role in respiratory pathology. Beyond this, we were able to detect significant effects of rare allelic variants. Conversely, this study design by definition excludes variants on other genes. While this is a limitation of the current study, given the hypoxemia dependent stabilization of HIF-1 α and the experimental data supporting a role of HIF-1 α in pulmonary conditions as outlined above it seemed reasonable to focus on *HIF1A*. Future studies may expand on the current

HIF-1a PheWAS

work by including other members of the HIF family. Furthermoree, knowing that SNPs within the *HIF1A* gene are associated with respiratory diseases future studies can now refine our understanding of the associated phenotypes by looking at differences between patients with and without these SNPs.

DATA AVAILABILITY STATEMENT

The data analyzed in this study is subject to the following licenses/ restrictions: Some of the data used are available in deidentified format in dbGaP. Requests to access these datasets should be directed to https://www.ncbi.nlm.nih.gov/gap/.

AUTHOR CONTRIBUTIONS

JK: Conceptualization, Methodology, writing original draft, reviewing, editing. XC: Conceptualization, Methodology, formal analysis, data curation, reviewing, editing, visualization. MM and FM: Methodology, validation, data curation, reviewing.

REFERENCES

- Abraham, G., and Inouye, M. (2014). Fast Principal Component Analysis of Large-Scale Genome-wide Data. *PloS one* 9 (4), e93766. doi:10.1371/ journal.pone.0093766
- Altshuler, D. M., Gibbs, R. A., Peltonen, L., Altshuler, D. M., Gibbs, R. A., Peltonen, L., et al. (2010). Integrating Common and Rare Genetic Variation in Diverse Human Populations. *Nature* 467 (7311), 52–58. doi:10.1038/nature09298
- Auton, A., Auton, A., Brooks, L. D., Durbin, R. M., Garrison, E. P., Kang, H. M., et al. (2015). A Global Reference for Human Genetic Variation. *Nature* 526 (7571), 68–74. doi:10.1038/nature15393
- Baumann, A. A., and Cabassa, L. J. (2020). Reframing Implementation Science to Address Inequities in Healthcare Delivery. *BMC Health Serv. Res.* 20 (1), 190. doi:10.1186/s12913-020-4975-3
- Bush, W. S., Oetjens, M. T., and Crawford, D. C. (2016). Unravelling the Human Genome-Phenome Relationship Using Phenome-wide Association Studies. *Nat. Rev. Genet.* 17 (3), 129–145. doi:10.1038/nrg.2015.36
- Carroll, R. J., Bastarache, L., and Denny, J. C., and (2014). R PheWAS: Data Analysis and Plotting Tools for Phenome-wide Association Studies in the R Environment. *Bioinformatics* 30 (16), 2375–2376. doi:10.1093/bioinformatics/ btu197
- Chan, C. H. T., Munusamy, P., Loke, S. Y., Koh, G. L., Wong, E. S. Y., Law, H. Y., et al. (2017). Identification of Novel Breast Cancer Risk Loci. *Cancer Res.* 77 (19), 5428–5437. doi:10.1158/0008-5472.can-17-0992
- Chang, C. C., Chow, C. C., Tellier, L. C., Vattikuti, S., Purcell, S. M., and Lee, J. J. (2015). Second-generation PLINK: Rising to the Challenge of Larger and Richer Datasets. *GigaScience* 4, 7. doi:10.1186/s13742-015-0047-8
- Danecek, P., Bonfield, J. K., Liddle, J., Marshall, J., Ohan, V., Pollard, M. O., et al. (2021). Twelve Years of SAMtools and BCFtools. *GigaScience* 10 (2), giab008. doi:10.1093/gigascience/giab008
- Das, S., Forer, L., Schönherr, S., Sidore, C., Locke, A. E., Kwong, A., et al. (2016). Next-generation Genotype Imputation Service and Methods. *Nat. Genet.* 48 (10), 1284–1287. doi:10.1038/ng.3656
- Fuchsberger, C., Abecasis, G. R., and Hinds, D. A. (2015). Minimac2: Faster Genotype Imputation. *Bioinformatics* 31 (5), 782–784. doi:10.1093/ bioinformatics/btu704
- Ghoussaini, M., Mountjoy, E., Carmona, M., Peat, G., Schmidt, E. M., Hercules, A., et al. (2021). Open Targets Genetics: Systematic Identification of Trait-Associated Genes Using Large-Scale Genetics and Functional Genomics. *Nucleic Acids Res.* 49 (D1), D1311–D1320. doi:10.1093/nar/gkaa840

PS: Conceptualization, Methodology, reviewing. HH: Conceptualization, Methodology, reviewing, editing, Supervision.

FUNDING

This work was supported by Institutional Development Funds and the Endowed Chair in Genomic Research grant from The Children's Hospital of Philadelphia. Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under award number TL1TR001880. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

ACKNOWLEDGMENTS

We thank the patients and their families for their participation in the respective genotyping studies and the Biobank Repository at the Center for Applied Genomics.

- Gladek, I., Ferdin, J., Horvat, S., Calin, G. A., and Kunej, T. (2017). HIF1Agene Polymorphisms and Human Diseases: Graphical Review of 97 Association Studies. *Genes Chromosom. Cancer* 56 (6), 439–452. doi:10.1002/gcc.22449
- Gottesman, O., Kuivaniemi, H., Kuivaniemi, H., Tromp, G., Faucett, W. A., Li, R., et al. (2013). The Electronic Medical Records and Genomics (eMERGE) Network: Past, Present, and Future. *Genet. Med.* 15 (10), 761–771. doi:10.1038/gim.2013.72
- Hlatky, M. A., Quertermous, T., Boothroyd, D. B., Priest, J. R., Glassford, A. J., Myers, R. M., et al. (2007). Polymorphisms in Hypoxia Inducible Factor 1 and the Initial Clinical Presentation of Coronary Disease. *Am. Heart J.* 154 (6), 1035–1042. doi:10.1016/j.ahj.2007.07.042
- Hoang, T. T., Manso, P. H., Edman, S., Mercer-Rosa, L., Mitchell, L. E., Sewda, A., et al. (2019). Genetic Variants of HIF1a Are Associated with Right Ventricular Fibrotic Load in Repaired Tetralogy of Fallot Patients: A Cardiovascular Magnetic Resonance Study. J. Cardiovasc. Magn. Reson. 21 (1), 51. doi:10.1186/s12968-019-0555-2
- Huang, Y., Jin, L., Yu, H., Jiang, G., Tam, C. H. T., Jiang, S., et al. (2020). SNPs in PRKCA-Hifla-GLUT1 Are Associated with Diabetic Kidney Disease in a Chinese Han Population with Type 2 Diabetes. *Eur. J. Clin. Invest.*,50 (9), e13264. doi:10.1111/eci.13264
- Huerta-Yepez, S., Baay-Guzman, G. J., Garcia-Zepeda, R., Hernandez-Pando, R., Vega, M. I., Gonzalez-Bonilla, C., et al. (2008). 2-Methoxyestradiol (2-ME) Reduces the Airway Inflammation and Remodeling in an Experimental Mouse Model. *Clin. Immunol.* 129 (2), 313–324. doi:10.1016/j.clim.2008.07.023
- Karczewski, K. J., Francioli, L. C., Tiao, G., Cummings, B. B., Alföldi, J., Wang, Q., et al. (2020). The Mutational Constraint Spectrum Quantified From Variation in 141,456 Humans. *Nature* 581 (7809), 434–443. doi:10.1038/s41586-020-2308-7
- Ke, Q., and Costa, M. (2006). Hypoxia-inducible Factor-1 (HIF-1). Mol. Pharmacol. 70 (5), 1469–1480. doi:10.1124/mol.106.027029
- Kilani, M. M., Mohammed, K. A., Nasreen, N., Tepper, R. S., and Antony, V. B. (2004). RSV Causes HIF-1α Stabilization via NO Release in Primary Bronchial Epithelial Cells. *Inflammation* 28 (5), 245–251. doi:10.1007/ s10753-004-6047-y
- Kim, S. R., Lee, K. S., Park, H. S., Park, S. J., Min, K. H., Moon, H., et al. (2010). HIF-1α Inhibition Ameliorates an Allergic Airway Disease via VEGF Suppression in Bronchial Epithelium. *Eur. J. Immunol.* 40 (10), 2858–2869. doi:10.1002/ eji.200939948
- Majmundar, A. J., Wong, W. J., and Simon, M. C. (2010). Hypoxia-inducible Factors and the Response to Hypoxic Stress. *Mol. Cel.* 40 (2), 294–309. doi:10.1016/j.molcel.2010.09.022

- McLaren, W., Gil, L., Hunt, S. E., Riat, H. S., Ritchie, G. R. S., Thormann, A., et al. (2016). The Ensembl Variant Effect Predictor. *Genome Biol.* 17 (1), 122. doi:10.1186/s13059-016-0974-4
- Nava-Salazar, S., Sánchez-Rodríguez, E. N., Mendoza-Rodríguez, C. A., Moran, C., Romero-Arauz, J. F., and Cerbón, M. A. (2011). Polymorphisms in the Hypoxia-Inducible Factor 1 Alpha Gene in Mexican Patients with Preeclampsia: A Case-Control Study. *BMC Res. Notes* 4 (1), 68. doi:10.1186/ 1756-0500-4-68
- Paradowska-Gorycka, A., Stypinska, B., Pawlik, A., Haladyj, E., Romanowska-Próchnicka, K., and Olesinska, M. (2018). HIF-1A Gene Polymorphisms and its Protein Level in Patients with Rheumatoid Arthritis: a Case-Control Study. *Inflamm. Res.* 67 (5), 423–433. doi:10.1007/s00011-018-1134-y
- Phan Yj, L., Zhang, H., Qiang, W., Shekhtman, E., Shao, D., Revoe, D., et al. (2020). ALFA: Allele Frequency Aggregator. Bethesda, MD: National Center for Biotechnology Information, US National Library of Medicine.
- Shimoda, L. A., and Semenza, G. L. (2011). HIF and the Lung. Am. J. Respir. Crit. Care Med. 183 (2), 152–156. doi:10.1164/rccm.201009-1393pp
- Slemc, L., and Kunej, T. (2016). Transcription Factor HIF1A: Downstream Targets, Associated Pathways, Polymorphic Hypoxia Response Element (HRE) Sites, and Initiative for Standardization of Reporting in Scientific Literature. *Tumor Biol.* 37 (11), 14851–14861. doi:10.1007/s13277-016-5331-4
- Taliun, D., Harris, D. N., Kessler, M. D., Carlson, J., Szpiech, Z. A., Torres, R., et al. (2021). Sequencing of 53,831 Diverse Genomes from the NHLBI TOPMed Program. *Nature* 590 (7845), 290–299. doi:10.1038/s41586-021-03205-y
- Wang, D., Fan, Y., Malhi, M., Bi, R., Wu, Y., Xu, M., et al. (2018). Missense Variants in HIF1A and LACC1 Contribute to Leprosy Risk in Han Chinese. Am. J. Hum. Genet. 102 (5), 794–805. doi:10.1016/j.ajhg.2018.03.006

- Wang, G. L., and Semenza, G. L. (1993). General Involvement of Hypoxia-Inducible Factor 1 in Transcriptional Response to Hypoxia. Proc. Natl. Acad. Sci. 90 (9), 4304–4308. doi:10.1073/pnas.90.9.4304
- Ward, L. D., and Kellis, M. (2012). HaploReg: A Resource for Exploring Chromatin States, Conservation, and Regulatory Motif Alterations Within Sets of Genetically Linked Variants. *Nucleic Acids Res.* 40 (Database issue), D930–D934. doi:10.1093/nar/gkr917
- Yu, A. Y., Frid, M. G., Shimoda, L. A., Wiener, C. M., Stenmark, K., and Semenza, G. L. (1998). Temporal, Spatial, and Oxygen-Regulated Expression of Hypoxia-Inducible Factor-1 in the Lung. *Am. J. Physiol. Lung Cell Mol. Physiol.* 275 (4), L818–L826. doi:10.1152/ajplung.1998.275.4.1818

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Kelchtermans, Chang, March, Mentch, Sleiman and Hakonarson. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.